Physician profile
Richard E Jones
NPI 1174507800
$126,257.04
in general payments reported to CMS, 2019-2025
39 companies · $4,096 in 2025
The $4,096 reported for 2025 was more than what 83% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $24K · 2021: $27K · 2022: $26K · 2023: $8,234 · 2024: $4,223 · 2025: $4,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Honoraria: $1,300 · Education: $493 · Travel and Lodging: $75.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,185.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Honoraria | $1,300.00 |
| Education | $492.97 |
| Travel and Lodging | $75.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $39,419.44 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $19,946.00 | 2021-2025 | Lupkynis |
| Abbvie INC. | $17,705.14 | 2019-2025 | |
| Genentech USA, INC. | $10,257.82 | 2019-2025 | Actemra, Gazyva |
| Celgene Corporation | $9,552.75 | 2019 | |
| Amgen INC. | $6,962.42 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Mallinckrodt Enterprises LLC | $5,821.24 | 2019 | |
| Ani Pharmaceuticals, INC. | $3,022.52 | 2022-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $2,396.32 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,712.20 | 2019-2025 | |
| Janssen Biotech, INC. | $1,475.89 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $1,331.43 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,077.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $903.65 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $877.28 | 2021-2025 | Saphnelo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $658.49 | 2023-2025 | |
| Lilly USA, LLC | $586.93 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Alexion Pharmaceuticals, INC. | $461.81 | 2019-2024 | Strensiq |
| Horizon Therapeutics Plc | $460.21 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $400.79 | 2019-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.07 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $239.75 | 2019-2020 | |
| Kyowa Kirin, INC. | $139.84 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $123.21 | 2024 | Tremfya |
| Organon LLC | $84.54 | 2023-2025 | Renflexis, Hadlima, Nexplanon |
| Daiichi Sankyo INC. | $71.44 | 2019-2020 | |
| Medexus Pharma, INC. | $58.87 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $47.67 | 2019-2021 | |
| Sandoz INC. | $36.13 | 2023 | Hyrimoz |
| Bioventus LLC | $25.56 | 2021 | |
| Eusa Pharma (US) LLC | $22.37 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.58 | 2021 | |
| Fresenius Kabi USA, LLC | $18.74 | 2025 | |
| Invivyd INC | $18.48 | 2025 | Pemgarda |
| Hikma Pharmaceuticals USA | $14.02 | 2020 | |
| Boston Scientific Corporation | $13.18 | 2023 | Infinion 16 |
| Collegium Pharmaceutical, INC. | $12.99 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.